A clinical trial is a research study designed to evaluate the safety and effectiveness of new cancer treatment options. This type of research improves the treatment of cancer. As a result of these trials, cancer survival rates have increased, quality of life has improved and side effects have decreased for many patients.
Our Current Trials
BREAST
Adjuvant Endocrine Therapy
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence.
Locally advanced or metastatic, PIK3CA mutated
GENENTECH WO43919: A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the efficacy and safety of INAVOLISIB PLUS FULVESTRANT versus ALPELISIB PLUS FULVESTRANT in patients with hormone receptor positive (HR+), HER2-NEGATIVE, PIK3CA MUTATED, locally advanced or metastatic breast cancer who have progressed during or after CDK4/6 inhibitor and endocrine combination therapy
Locally advanced ER (+) HER2neu Neg
New! CO44657:A phase III, randomized, open-label study evaluating efficacy and safety of Giredestrant compared with Fulvestrant, both combined with a CDK4/6 Inhibitor, in patients with estrogen receptor positive, Her2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy.
Triple Negative Breast Cancer
New! MERCK 2870-012:A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery.
BLOOD DRAW
EXACT-SCIENCES
2021-05: Whole blood and tumor tissue specimens from subjects who either have a diagnosis of cancer or recurrent cancer to evaluate biomarkers.
COLON
Adjuvant CRC
BNT000-001 – Epidemiological study to monitor study participants with resected Stage II (high risk) or Stage III colorectal cancer for circulating tumor DNA before, during and after their treatment with adjuvant chemotherapy.
BNT122-01 – Multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (Main Trial).
PROSTATE
NRG-GU008: *INNOVATE: INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapy Randomized Phase III Trial incorporating apalutamide and advanced imaging into salvage treatment for patients with node positive prostate cancer after radical prostatectomy.
NRG-GU009:PREDICT-RT*/*Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation Parallel Phase III Randomized Trials for High Risk Prostate Cancer evaluation de-intensification for lower genomic risk and intensification of concurrent therapy for higher genomic risk with radiation.
NRG-GU010 GUIDANCE: Parallel Phase III Randomized Trials of Genomic-risk stratified Unfavorable Intermediate risk prostate cancer: De-intensification And Intensification Clinical trial Evaluation
RARE GENITOURINARY CANCER
A031072: A phase II study of Ipilimumab, Cabozantinig and Nivolumab in rare Genitourinary Cancer (ICONIC)
- Cohort A: Small cell carcinoma/neuroendocrine of the bladder)
- Cohort C: Squamous cell carcinoma.
- Cohort D: Plasmacytoid urothelial carcinoma.
- Cohort H: Sarcomatoid urothelial carcinoma
- Cohort J: non-prostate bone only metastatic GU tumors
- Cohort K: Renal Collecting duct carcinoma
- Cohort L: Urethra carcinoma.
Multiple Tumor Types
MK-3475A-F11: A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Co-formulated with Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants
- Resected stage IIB, IIC, III melanoma CLOSED
- Intermediate-high or high risk resected RCC CLOSED
- Newly diagnosed untreated stage IV NSCLC w a PD-L1 TPS ≥ 50%
How Can I Participate in a Clinical Trial?
We have a number of trials available and will offer one to you if appropriate. Keep in mind that most clinical trials have strict eligibility criteria to protect patients and provide the best chance for success. Age, gender, cancer type and prior treatments may be included in the selection criteria. That means not all patients are eligible for a clinical trial.
What are the phases of a Clinical Trial?
Phase I trials assess the safety of a new medication or treatment.
Phase II trials also assess the safety of a new medication or treatment, but often measure the effectiveness of those treatments as well.
Phase III trials measure the effectiveness and safety of a new medication or treatment compared to the existing best practice.
What if I Get a Placebo?
Cancer patients participating in clinical trials will always receive a treatment that is equivalent to, or possibly better than, the standard treatment. Placebo trials are never used when there is a potentially effective therapy available. Your doctor and research team can explain the details of placebo-controlled trials to you during your office visits.
Will My Clinical Trial Work?
There’s no guarantee that your clinical trial will work. However, before every clinical trial starts, the designers of the trial must present evidence that convinces the Food and Drug Administration (FDA) that the trial is a logical treatment option.
Can I Quit My Clinical Trial?
Participation in clinical trials is completely voluntary. Every participant in a clinical trial signs an informed consent form that outlines the trial’s potential benefits and risks. During the trial, the research team will monitor you closely and help manage any side effects you may experience. You can decide to stop participating in the trial at any time.